Word: ebright
(lookup in dictionary)
(lookup stats)
Dates: during 2000-2009
Sort By: most recent first
(reverse)
...don’t think that’s what the sport’s about.” Nevertheless, he said he expects the line to do well. So far, Status Flow has found distribution online and with mid-Atlantic boutique Urban Chic. Alexandra R. Ebright, store manager and merchandiser at the chain’s Baltimore location, said that sales have been “great.” Ebright said she already sees the line as cornering an unexpected market: “It has sold really well to our guy customers just looking for something that...
Armed with a new biochemical understanding of how myxopyronin functions, along with detailed models of its behavior inside bacterial cells, researchers say drug development is feasible at last. Ebright says the drug could be in clinical human trials within five years. "What has not been possible previously was design of new derivatives ," says Ebright. "It's now possible to make new derivatives that are expressly designed to...have higher potency...
...would say that most of the American public believe that bacterial infections were conquered with the discovery of penicillin and streptomycin and that the dawn of the antibiotic age meant the end of bacterial infection as an important threat," says Richard Ebright, a Howard Hughes Medical Institute investigator at Rutgers and a co-author on the study...
...Ebright hopes myxopyronin will be especially useful in the battle against drug-resistant tuberculosis, a disease for which clinicians have never had a perfect therapy. The success of TB treatment depends on the destruction of active and dormant bacteria to prevent relapse - something that few existing antibiotics have been able to do. One way to kill a dormant cell is to target biochemical processes that continue even in latency - there aren't many of those. But myxopyronin works by interfering with the enzyme RNA polymerase, which controls gene transcription in cells and is necessary for cell survival, dormant...
...many experts disagree, calling into question the focus of biological research in the U.S. - on anthrax and plague instead of, say, drug-resistant tuberculosis or the hepatitis viruses - which may be doing the country a disservice. In a 2005 open letter, organized by Richard H. Ebright, a Rutgers University chemistry professor, 758 American microbiologists complained that NIH priorities favoring research of "high bio-defense significance but low public-heath significance" were misguided and jeopardized public health progress...